NT5E and neoplasm: Anti-CD73 monoclonal antibodies, in models such as breast cancer (4T1.2/E0771) (96) and head and neck squamous cell carcinoma (97), not only suppressed primary tumor growth and metastasis by inducing adaptive antitumor immunity but also reversed T-cell exhaustion.